Frontlight ResearchEarly access
CompletedNo phase
One-shot Ovarian Stimulation Protocol (One-shot)
Key facts
- Who runs it
- Fundación Santiago Dexeus Font
- Where
- Spain3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 31 Oct 2024
- Ended
- 11 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1
- Clomiphene Citrate (CC) 100 mg/day from D1
- Monitoring cycle
- Record updated
- 8 September 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age <= 40
- AMH (Anti-Mullerian Hormone) 1.2-3.5 ng/ml or AFC 7-20
- No family history of hereditary or chromosomal diseases
- Body mass index (BMI) 18 to 30 kg/m2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).
The group in the trial
- Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1Treatment being tested
Treatment: Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1, Clomiphene Citrate (CC) 100 mg/day from D1, and Monitoring cycle
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- One-Shot Ovarian Stimulation Protocol: A Pilot Study Investigating the Endocrine Profile
- Record updated
- 8 September 2026